Surface-PASylation of ferritin to form stealth nanovehicles
enhances in vivo therapeutic performance of encapsulated
ellipticine

J 2020

Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine

TESAROVA, B., S. DOSTALOVA, V. SMIDOVA, Zita GOLIÁŠOVÁ, Z. SKUBALOVA et. al.

Basic information

Original name

Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine

Authors

TESAROVA, B. (203 Czech Republic), S. DOSTALOVA (203 Czech Republic), V. SMIDOVA (203 Czech Republic), Zita GOLIÁŠOVÁ (203 Czech Republic), Z. SKUBALOVA (203 Czech Republic), H. MICHALKOVA (203 Czech Republic), H. DAVID (203 Czech Republic), P. MICHALEK (203 Czech Republic), Hana POLANSKÁ (203 Czech Republic, belonging to the institution), M. VACUOVICOVA (203 Czech Republic), J. HACEK (203 Czech Republic), T. ECKSCHLAGER (203 Czech Republic), M. STIBOROVA (203 Czech Republic), A. S. PIRES (620 Portugal), A. R. M. NEVES (620 Portugal), A. M. ABRANTES (620 Portugal), T. RODRIGUES (620 Portugal), P. MATAFOME (620 Portugal), M. F. BOTELHO (620 Portugal), P. TEIXEIRA (620 Portugal), F. MENDES (620 Portugal) and Z. HEGER (203 Czech Republic, guarantor)

Edition

APPLIED MATERIALS TODAY, AMSTERDAM, ELSEVIER SCIENCE BV, 2020, 2352-9407

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30404 Biomaterials

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 10.041

RIV identification code

RIV/00216224:14110/20:00115972

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.apmt.2019.100501

UT WoS

000530652300014

Keywords in English

Biocompatibility; Breast carcinoma; Cancer therapy; Ferritin; PASylation; PEGylation

Abstract

V originále

Surface functionalisations substantially influence the performance of drug delivery vehicles by improving their biocompatibility, selectivity and circulation in bloodstream. Herein, we present the study of in vitro and in vivo behaviour of a highly potent cytostatic alkaloid ellipticine (Elli) encapsulated in internal cavity of ferritin (FRT)-based nanocarrier (hereinafter referred to as FRTElli). In addition, FRTElli surface was functionalised with three different molecular coatings: two types of protective PAS peptides (10- or 20-residues lengths) with sequences comprising amino acids proline (P), alanine (A) and serine (S) (to form PAS-10-FRTElli or PAS-20-FRTElli, respectively), or polyethylene glycol (PEG-FRTElli). All three surface modifications of FRT disposed sufficient encapsulation efficiency of Elli with no premature cumulative release of cargo. Noteworthy, all tested surface modifications displayed beneficial effects on the in vitro biocompatibility. PAS-10-FRTElli exhibited markedly reduced uptake by macrophages compared to PAS-20-FRTElli, PEG-FRTElli or unmodified FRTElli. The exceptional properties of PAS-10-FRTElli were validated by an array of in vitro analyses including formation of protein corona, uptake efficiency or screenings of selectivity of cytotoxicity. In murine preclinical model bearing triple -negative breast cancer (MDA-MB-231) xenograft, compared to free Elli or FRTElli, PAS-10-FRTElli displayed enhanced accumulation of Elli within tumour tissue, while hampering the uptake of Elli into off-target tissues. Noteworthy, PAS-10-FRTElli led to decreased in vivo complement (C3) activation and protein corona formation. Taken together, presented in vivo results indicate that PAS-10-FRTElli represents a promising stealth platform for translation into clinical settings. (C) 2019 Elsevier Ltd. All rights reserved.

Links

LQ1601, research and development project

Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

TESAROVA, B., S. DOSTALOVA, V. SMIDOVA, Zita GOLIÁŠOVÁ, Z. SKUBALOVA, H. MICHALKOVA, H. DAVID, P. MICHALEK, Hana POLANSKÁ, M. VACUOVICOVA, J. HACEK, T. ECKSCHLAGER, M. STIBOROVA, A. S. PIRES, A. R. M. NEVES, A. M. ABRANTES, T. RODRIGUES, P. MATAFOME, M. F. BOTELHO, P. TEIXEIRA, F. MENDES and Z. HEGER. Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine. APPLIED MATERIALS TODAY. AMSTERDAM: ELSEVIER SCIENCE BV, 2020, vol. 18, MAR 2020, p. 1-11. ISSN 2352-9407. Available from: https://dx.doi.org/10.1016/j.apmt.2019.100501.

@article{1670256,
   author = {Tesarova, B. and Dostalova, S. and Smidova, V. and Goliášová, Zita and Skubalova, Z. and Michalkova, H. and David, H. and Michalek, P. and Polanská, Hana and Vacuovicova, M. and Hacek, J. and Eckschlager, T. and Stiborova, M. and Pires, A. S. and Neves, A. R. M. and Abrantes, A. M. and Rodrigues, T. and Matafome, P. and Botelho, M. F. and Teixeira, P. and Mendes, F. and Heger, Z.},
   article_location = {AMSTERDAM},
   article_number = {MAR 2020},
   doi = {http://dx.doi.org/10.1016/j.apmt.2019.100501},
   keywords = {Biocompatibility; Breast carcinoma; Cancer therapy; Ferritin; PASylation; PEGylation},
   language = {eng},
   issn = {2352-9407},
   journal = {APPLIED MATERIALS TODAY},
   title = {Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine},
   url = {https://www.sciencedirect.com/science/article/pii/S2352940719306201?via%3Dihub},
   volume = {18},
   year = {2020}
}

TY  - JOUR
ID  - 1670256
AU  - Tesarova, B. - Dostalova, S. - Smidova, V. - Goliášová, Zita - Skubalova, Z. - Michalkova, H. - David, H. - Michalek, P. - Polanská, Hana - Vacuovicova, M. - Hacek, J. - Eckschlager, T. - Stiborova, M. - Pires, A. S. - Neves, A. R. M. - Abrantes, A. M. - Rodrigues, T. - Matafome, P. - Botelho, M. F. - Teixeira, P. - Mendes, F. - Heger, Z.
PY  - 2020
TI  - Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine
JF  - APPLIED MATERIALS TODAY
VL  - 18
IS  - MAR 2020
SP  - 1-11
EP  - 1-11
PB  - ELSEVIER SCIENCE BV
SN  - 23529407
KW  - Biocompatibility
KW  - Breast carcinoma
KW  - Cancer therapy
KW  - Ferritin
KW  - PASylation
KW  - PEGylation
UR  - https://www.sciencedirect.com/science/article/pii/S2352940719306201?via%3Dihub
L2  - https://www.sciencedirect.com/science/article/pii/S2352940719306201?via%3Dihub
N2  - Surface functionalisations substantially influence the performance of drug delivery vehicles by improving their biocompatibility, selectivity and circulation in bloodstream. Herein, we present the study of in vitro and in vivo behaviour of a highly potent cytostatic alkaloid ellipticine (Elli) encapsulated in internal cavity of ferritin (FRT)-based nanocarrier (hereinafter referred to as FRTElli). In addition, FRTElli surface was functionalised with three different molecular coatings: two types of protective PAS peptides (10- or 20-residues lengths) with sequences comprising amino acids proline (P), alanine (A) and serine (S) (to form PAS-10-FRTElli or PAS-20-FRTElli, respectively), or polyethylene glycol (PEG-FRTElli). All three surface modifications of FRT disposed sufficient encapsulation efficiency of Elli with no premature cumulative release of cargo. Noteworthy, all tested surface modifications displayed beneficial effects on the in vitro biocompatibility. PAS-10-FRTElli exhibited markedly reduced uptake by macrophages compared to PAS-20-FRTElli, PEG-FRTElli or unmodified FRTElli. The exceptional properties of PAS-10-FRTElli were validated by an array of in vitro analyses including formation of protein corona, uptake efficiency or screenings of selectivity of cytotoxicity. In murine preclinical model bearing triple -negative breast cancer (MDA-MB-231) xenograft, compared to free Elli or FRTElli, PAS-10-FRTElli displayed enhanced accumulation of Elli within tumour tissue, while hampering the uptake of Elli into off-target tissues. Noteworthy, PAS-10-FRTElli led to decreased in vivo complement (C3) activation and protein corona formation. Taken together, presented in vivo results indicate that PAS-10-FRTElli represents a promising stealth platform for translation into clinical settings. (C) 2019 Elsevier Ltd. All rights reserved.
ER  -

TESAROVA, B., S. DOSTALOVA, V. SMIDOVA, Zita GOLIÁŠOVÁ, Z. SKUBALOVA, H. MICHALKOVA, H. DAVID, P. MICHALEK, Hana POLANSKÁ, M. VACUOVICOVA, J. HACEK, T. ECKSCHLAGER, M. STIBOROVA, A. S. PIRES, A. R. M. NEVES, A. M. ABRANTES, T. RODRIGUES, P. MATAFOME, M. F. BOTELHO, P. TEIXEIRA, F. MENDES and Z. HEGER. Surface-PASylation of ferritin to form stealth nanovehicles enhances in vivo therapeutic performance of encapsulated ellipticine. \textit{APPLIED MATERIALS TODAY}. AMSTERDAM: ELSEVIER SCIENCE BV, 2020, vol.~18, MAR 2020, p.~1-11. ISSN~2352-9407. Available from: https://dx.doi.org/10.1016/j.apmt.2019.100501.

Detailed Information on Publication Record